caused, revenue from sales of domestic and export decreased about 5% and 16% respectively. Analysis of Profit of company and its subsidiaries The Q2/2019, the company and its subsidiaries have loss for the

caused, revenue from sales of domestic and export decreased about 20% and 12% respectively. Analysis of Profit of company and its subsidiaries The Q1/2018, the company and its subsidiaries have loss for

1.75 times. (as at 31 December 2019 is 1.90 times). Operating result The consolidated net profit of the Company and its subsidiary for the period 3-month ended 31 March 2020 was Baht 34.60 million

subsidiary for Quarter 1 of 2020 ending on 31 March 2020 as follows; Statements of Comprehensive Income Revenue from medical treatment The Company generated the revenue from medical treatment for the 1st

) -13.0% EBITDA 131.6 251.0 -47.6% 319.5 -58.8% Finance cost (193.6) (189.2) 2.3% (111.0) 74.4% Share of profit/loss from JVs/associates (equity income) (22.5) 8.3 -369.7% 37.9 -159.3% Reported Net Profit

profit/(loss) from investment 27 1 16 0 15 0 (13) (47) (2) (10) 80 1 60 0 (20) (25) Income Tax Expenses (15) (0) 9 0 6 0 21 (137) (3) (37) (14) (0) 2 0 17 (115) Net Profit 204 5 71 1 55 1 (149) (73) (16

from organizing concerts (20.74) (108.08) - - Selling cost (1.31) (6.82) - - Total cost (22.05) (114.90) - - Gross profit (2.86) (14.90) 0.61 100.00 Other income 11.34 59.09 10.80 1,770.49 Profit before

in sales and overall gross profit margin and effective management over selling and admin expenses, which compensated higher financial expenses and corporate income tax expenses as mentioned above. Net

million baht or 10.4 percent. The company reported profit for Q2/2017 of 4.9 million baht compared with reported loss for Q2/2016 of 6.1 million baht. For the six-month period of 2017, the consolidated

Baht 0.94 million and 0.04 million respectively. The proportion of income tax to the total revenues were 0.3%.and 0.0% respectively. Net Profit The Company’s net profits for the 6-month period of 2016